PFE241227P27500
- 0.92
- 0.000.00%
Pfizer Newsroom
5 Stocks That Could Get a Bump From Activist Investors
Sector Update: Health Care Stocks Softer Late Afternoon
Sector Update: Health Care
Bulls Vs. Bears: Is the Schwab U.S. Dividend Equity ETF a Good Investment?
Top Research Reports for Berkshire Hathaway, Home Depot & Pfizer
Pfizer Joins Forces With Atavistik Bio to Unlock Revolutionary Cancer Treatments
Unusual Options Activity: CZR, EL and Others Attract Market Bets, CZR V/OI Ratio Reaches 356.7
Pfizer, Atavistik to Collaborate on Allosteric Drug Discovery
Here's Why Pfizer (PFE) Is a Strong Momentum Stock
Pfizer Hits 7-week High
Atavistik Bio Has Entered Into A Research Collaboration With Pfizer For Precision Allosteric Therapeutics, Leveraging Atavistik Bio's Platform To Identify And Validate Allosteric Binders Against Two Undisclosed, Pfizer-designated Targets, Financial...
Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership -- Barrons.com
Express News | Atavistik Bio: Financial Terms of Collaboration Are Undisclosed
Express News | Atavistik Bio: Research Collaboration With Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics
Jim Cramer's Take on Pfizer Inc. (PFE): Bold Predictions for the Future
Brand Prescription Drugs to Rise an Average 4.5% in 2025
How Is The Market Feeling About Pfizer?
Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More. -- Barrons.com
Pfizer Options Spot-On: On December 31st, 123.35K Contracts Were Traded, With 3.22 Million Open Interest
US Equities Markets End Lower Tuesday In Last Trading Session of 2024